Comparative Pharmacology
Head-to-head clinical analysis: MAXOLON versus MECLODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXOLON versus MECLODIUM.
MAXOLON vs MECLODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metoclopramide, the active ingredient in MAXOLON, is a dopamine D2 receptor antagonist and also enhances the response to acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to increased gastric motility and accelerated gastric emptying. It also has antiemetic effects by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ).
Meclodium is a synthetic flavonoid derivative with antioxidant and anti-inflammatory properties. It inhibits lipid peroxidation and scavenges free radicals, protecting cell membranes from oxidative damage. It also modulates immune responses by reducing pro-inflammatory cytokine production.
10 mg orally, intramuscularly, or intravenously three to four times daily. Maximum daily dose: 30 mg or 0.5 mg/kg.
Not a recognized drug.
None Documented
None Documented
5-6 hours in adults with normal renal function; prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 85-95% as unchanged drug and metabolites; biliary/fecal: <5%.
Renal: 70% unchanged; Biliary/fecal: 20% as metabolites; 10% minor pathways.
Category C
Category C
Antiemetic
Antiemetic